Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
AssigneesPfizer Inc., Merck Sharp & Dohme Corp.
InventorsJean-Francois Andre Martini, Jamal Christo Tarazi, Rodolfo Fleury Perini, David J. Mauro
Life of this patent
Estimating the term…
Abstract
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
Claims21
-19. (canceled)
A medicament comprising
- pembrolizumab for use in combination with axitinib for treating renal cell carcinoma (RCC) in an individual by a method comprising administering to the individual axitinib at a dose of 5 milligrams (mg) two times a day (BID) and pembrolizumab at a dose of 200 mg every three weeks (Q3W).
A medicament comprising axitinib for use in combination with pembrolizumab for treating renal cell carcinoma (RCC) in an individual by a method comprising administering to the individual axitinib at a dose of 5 milligrams (mg) two times a day (BID) and pembrolizumab at a dose of 200 mg every three weeks (Q3W).
Dependencies are inferred from the claim text.